Cargando…

2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function

OBJECTIVES/SPECIFIC AIMS: Insufficient endogenous expression of suppressor of cytokine signaling 3 (SOCS3) with subsequent over-activation of its target, the transcription factor STAT3, has been associated with tumorigenesis and cancer development in the lung and other organs. We have observed that...

Descripción completa

Detalles Bibliográficos
Autores principales: Speth, Jennifer, Penke, Loka R., Bazzill, Joseph, Arenberg, Douglas A., Moon, James J., Keshamouni, Venkateshwar G., Lama, Vibha N., Peters-Golden, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799327/
http://dx.doi.org/10.1017/cts.2018.148
_version_ 1783460259913793536
author Speth, Jennifer
Penke, Loka R.
Bazzill, Joseph
Arenberg, Douglas A.
Moon, James J.
Keshamouni, Venkateshwar G.
Lama, Vibha N.
Peters-Golden, Marc
author_facet Speth, Jennifer
Penke, Loka R.
Bazzill, Joseph
Arenberg, Douglas A.
Moon, James J.
Keshamouni, Venkateshwar G.
Lama, Vibha N.
Peters-Golden, Marc
author_sort Speth, Jennifer
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Insufficient endogenous expression of suppressor of cytokine signaling 3 (SOCS3) with subsequent over-activation of its target, the transcription factor STAT3, has been associated with tumorigenesis and cancer development in the lung and other organs. We have observed that a “backup” source of SOCS3 in the lung, namely that secreted in microvesicles (MVs) by alveolar macrophages, is reduced in the bronchoalveolar lavage fluid (BALF) of KRAS mutant mice harboring lung tumors. Here we sought to evaluate levels of SOCS3 in BALF of a cohort of non-small cell lung cancer (NSCLC) patients and to test the effects of vesicular SOCS3 administration on tumor cell transformation and function as potential therapeutic strategy. METHODS/STUDY POPULATION: In total, 22 BALF samples were obtained from healthy volunteers (n=11) as well as patients undergoing diagnostic bronchoscopies for suspected lung cancer (n=11). SOCS3 levels in the BALF were determined by ELISA after brief sonication to disrupt vesicles. In vitro experiments utilized the human adenocarcinoma cell line (A549) or human G12V mutant KRAS-expressing rat lung epithelial cells (RLE-G12V). Proliferation, Fas ligand (FasL)-induced apoptosis, and chemical transformation with N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) or cigarette smoke extract (CSE) were assessed by CyQuant assay, annexin V staining, and soft agar assay, respectively. For SOCS3 rescue, epithelial cells were treated with natural alveolar macrophages-derived MVs (isolated via ultracentrifugation) or synthetic unilamellar liposomes containing human recombinant SOCS3 for at least 1 hour before assay. RESULTS/ANTICIPATED RESULTS: SOCS3 levels were significantly reduced in BALF samples of patients determined to have NSCLC as compared with healthy volunteers (186.6±26.74 vs. 395.6±74.31 pg/mL, p=0.015, n=11). Addition of exogenous SOCS3-containing liposomes had the capacity to significantly inhibit MNNG and cigarette smoke extract-induced transformation and colony formation in soft agar. Exogenous SOCS3 provided in liposomes or in natural MVs significantly induced apoptosis (both in the presence and absence of FasL) and inhibited basal proliferation of A549 cells. DISCUSSION/SIGNIFICANCE OF IMPACT: These data identified a novel dysregulation of immune surveillance in the form of decreased SOCS3 secretion in the tumor-bearing lung that may contribute to tumorigenesis via sustained STAT3 activation. Future studies will focus on the mechanism underlying this defect and whether rescuing SOCS3 secretion can inhibit cancer progression in vivo.
format Online
Article
Text
id pubmed-6799327
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67993272019-10-28 2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function Speth, Jennifer Penke, Loka R. Bazzill, Joseph Arenberg, Douglas A. Moon, James J. Keshamouni, Venkateshwar G. Lama, Vibha N. Peters-Golden, Marc J Clin Transl Sci Basic/Translational Science/Team Science OBJECTIVES/SPECIFIC AIMS: Insufficient endogenous expression of suppressor of cytokine signaling 3 (SOCS3) with subsequent over-activation of its target, the transcription factor STAT3, has been associated with tumorigenesis and cancer development in the lung and other organs. We have observed that a “backup” source of SOCS3 in the lung, namely that secreted in microvesicles (MVs) by alveolar macrophages, is reduced in the bronchoalveolar lavage fluid (BALF) of KRAS mutant mice harboring lung tumors. Here we sought to evaluate levels of SOCS3 in BALF of a cohort of non-small cell lung cancer (NSCLC) patients and to test the effects of vesicular SOCS3 administration on tumor cell transformation and function as potential therapeutic strategy. METHODS/STUDY POPULATION: In total, 22 BALF samples were obtained from healthy volunteers (n=11) as well as patients undergoing diagnostic bronchoscopies for suspected lung cancer (n=11). SOCS3 levels in the BALF were determined by ELISA after brief sonication to disrupt vesicles. In vitro experiments utilized the human adenocarcinoma cell line (A549) or human G12V mutant KRAS-expressing rat lung epithelial cells (RLE-G12V). Proliferation, Fas ligand (FasL)-induced apoptosis, and chemical transformation with N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) or cigarette smoke extract (CSE) were assessed by CyQuant assay, annexin V staining, and soft agar assay, respectively. For SOCS3 rescue, epithelial cells were treated with natural alveolar macrophages-derived MVs (isolated via ultracentrifugation) or synthetic unilamellar liposomes containing human recombinant SOCS3 for at least 1 hour before assay. RESULTS/ANTICIPATED RESULTS: SOCS3 levels were significantly reduced in BALF samples of patients determined to have NSCLC as compared with healthy volunteers (186.6±26.74 vs. 395.6±74.31 pg/mL, p=0.015, n=11). Addition of exogenous SOCS3-containing liposomes had the capacity to significantly inhibit MNNG and cigarette smoke extract-induced transformation and colony formation in soft agar. Exogenous SOCS3 provided in liposomes or in natural MVs significantly induced apoptosis (both in the presence and absence of FasL) and inhibited basal proliferation of A549 cells. DISCUSSION/SIGNIFICANCE OF IMPACT: These data identified a novel dysregulation of immune surveillance in the form of decreased SOCS3 secretion in the tumor-bearing lung that may contribute to tumorigenesis via sustained STAT3 activation. Future studies will focus on the mechanism underlying this defect and whether rescuing SOCS3 secretion can inhibit cancer progression in vivo. Cambridge University Press 2018-11-21 /pmc/articles/PMC6799327/ http://dx.doi.org/10.1017/cts.2018.148 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic/Translational Science/Team Science
Speth, Jennifer
Penke, Loka R.
Bazzill, Joseph
Arenberg, Douglas A.
Moon, James J.
Keshamouni, Venkateshwar G.
Lama, Vibha N.
Peters-Golden, Marc
2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function
title 2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function
title_full 2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function
title_fullStr 2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function
title_full_unstemmed 2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function
title_short 2165 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC patients and its provision inhibits epithelial cell transformation and tumor cell function
title_sort 2165 vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in nsclc patients and its provision inhibits epithelial cell transformation and tumor cell function
topic Basic/Translational Science/Team Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799327/
http://dx.doi.org/10.1017/cts.2018.148
work_keys_str_mv AT spethjennifer 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction
AT penkelokar 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction
AT bazzilljoseph 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction
AT arenbergdouglasa 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction
AT moonjamesj 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction
AT keshamounivenkateshwarg 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction
AT lamavibhan 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction
AT petersgoldenmarc 2165vesicularsecretionofsuppressorofcytokinesignaling3byalveolarmacrophagesisdysregulatedinnsclcpatientsanditsprovisioninhibitsepithelialcelltransformationandtumorcellfunction